Table 2: Incidence rates for metastases by site.

Site of metastasisNumber starting trastuzumab without indicated metastasisNumber developing indicated metastasisIncidence rate (95% CI)

CNS56212514.1 (11.9–16.9)
Bone29310124.1 (19.8–29.3)
Liver3908613.5 (11.0–16.7)
Lung/Chest3788214.7 (11.8–18.2)
All Other4006810.7 (8.5–13.6)

Note: Rates estimated over all follow-up time and reported per 1,000 person-months of follow-up.